NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
22 December 2024
| Name: | PROTEOMICS INTERNATIONAL LABORATORIES LTD (PIQ) |
| ISIN: | AU000000PIQ0 |
| Date of Listing: | 16 April 2015 |
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 169 979 971ABN: 78 169 979 971
Registration Date: 09 June 2014
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
Automic Registry Pty Ltd
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Proteomics International Laboratories Ltd will be lifted immediately, following the release by PIQ of an announcement regarding an application for regulatory approval of the PromarkerD test in Australia and the reimbursement payment rate for the PromarkerD test in the United States. | 29/09/2023 |
Centers for Medicare & Medicaid Services list PromarkerD predictive test for diabetic kidney disease and assign payment rate of US$390.75 in the United States. CMS is the single largest payer for health care in the United States, with Medicare and Medicaid collectively responsible for 42 per cent of healthcare spending and providing health coverage to more than 100 million Americans. The Australian Therapeutic Goods Administration advises decision not to include the PromarkerD test in the Australian Register of Therapeutic Goods due primarily to change of manufacturer. TGA decision does not affect Proteomics International's activities in its primary markets of the United States and Europe. Approximately 32 million adults live with diabetes in the United States and 61 million in Europe, as compared to 1.5 million in Australia. | 29/09/2023 |
The Company requests an extension to the voluntary suspension of its securities pending the release of an announcement regarding the reimbursement payment rate for the PromarkerD test in the United States and the application for regulatory approval of the PromarkerD test in Australia. The Company estimates that it will be able to lodge an announcement on or before the commencement of trading on Monday, 2 October 2023. | 25/09/2023 |
The Company requests an extension to the voluntary suspension of its securities pending the release of an announcement regarding the application for regulatory approval of the PromarkerD test in Australia and the reimbursement payment rate for the PromarkerD test in the United States. The Company estimates that it will be able to lodge an announcement on or before the commencement of trading on Monday, 25 September 2023. | 20/09/2023 |
The securities of Proteomics International Laboratories Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of PIQ, pending the release of an announcement regarding an application for regulatory approval of the PromarkerD test in Australia and the reimbursement payment rate for the PromarkerD test in the United States. | 18/09/2023 |
The suspension of trading in the securities of Proteomics International Laboratories Ltd will be lifted immediately following the release by PIQ of an announcement regarding the licensing of the PromarkerD test in the US market. | 09/08/2022 |
Proteomics International and Sonic Healthcare USA sign binding and exclusive Letter of Intent regarding an exclusive licence for PromarkerD in the United States. Estimated 32 million people or eleven per cent of the American population live with diabetes - testing these patients with PromarkerD could help identify their risk of developing diabetic kidney disease. | 09/08/2022 |
The securities of Proteomics International Laboratories Ltd ("˜PIQ') will be suspended from quotation immediately under Listing Rule 17.2, at the request of PIQ, pending the release of an announcement. | 08/08/2022 |
The suspension of trading in the securities of Proteomics International Laboratories Ltd will be lifted from the commencement of trading on Monday, 5 July 2021, following the release by PIQ of an announcement regarding a presentation given at the American Diabetes Association's 81st Scientific Sessions, 25-29 June 2021. | 02/07/2021 |
Proteomics International Laboratories Ltd refers to its ASX release of 25 June 2021 titled "Modelling shows PromarkerD could save US payers $384 billion". Following consultation with ASX, and to ensure the findings from the study are not interpreted as forecast financial information under ASIC Regulatory Guide 170, Proteomics International has agreed to retract that Announcement. In retracting that Announcement, Proteomics International notes that investors should not rely on the information as a basis for making an investment decision about its shares. Importantly, shares in Proteomics International have not traded since release of the Announcement. The economic health benefit study was undertaken to support the Company's application for a unique reimbursement code for PromarkerD in the US, and was conducted by independent consultant, Boston Healthcare Associates. | 02/07/2021 |
The Company requests an extension to the voluntary suspension of its securities pending the release of an announcement regarding the presentation given at the American Diabetes Association's 81st Scientific Sessions, 25-29 June 2021. The Company estimates that it will be able to lodge an announcement on or before the commencement of trading on Tuesday, 6 July 2021. | 02/07/2021 |
The securities of Proteomics International Laboratories Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of PIQ, pending the release of the presentation given at the American Diabetes Association's 81st Scientific Sessions, 25-29 June 2021. | 29/06/2021 |
listed entity carried for record purposes only | 16/04/2015 |
The suspension of trading in the securities of Proteomics International Laboratories Ltd will be lifted immediately, following the release by PIQ of an announcement regarding an application for regulatory approval of the PromarkerD test in Australia and the reimbursement payment rate for the PromarkerD test in the United States. | 29/09/2023 |
Centers for Medicare & Medicaid Services list PromarkerD predictive test for diabetic kidney disease and assign payment rate of US$390.75 in the United States. CMS is the single largest payer for health care in the United States, with Medicare and Medicaid collectively responsible for 42 per cent of healthcare spending and providing health coverage to more than 100 million Americans. The Australian Therapeutic Goods Administration advises decision not to include the PromarkerD test in the Australian Register of Therapeutic Goods due primarily to change of manufacturer. TGA decision does not affect Proteomics International's activities in its primary markets of the United States and Europe. Approximately 32 million adults live with diabetes in the United States and 61 million in Europe, as compared to 1.5 million in Australia. | 29/09/2023 |
The Company requests an extension to the voluntary suspension of its securities pending the release of an announcement regarding the reimbursement payment rate for the PromarkerD test in the United States and the application for regulatory approval of the PromarkerD test in Australia. The Company estimates that it will be able to lodge an announcement on or before the commencement of trading on Monday, 2 October 2023. | 25/09/2023 |
The Company requests an extension to the voluntary suspension of its securities pending the release of an announcement regarding the application for regulatory approval of the PromarkerD test in Australia and the reimbursement payment rate for the PromarkerD test in the United States. The Company estimates that it will be able to lodge an announcement on or before the commencement of trading on Monday, 25 September 2023. | 20/09/2023 |
The securities of Proteomics International Laboratories Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of PIQ, pending the release of an announcement regarding an application for regulatory approval of the PromarkerD test in Australia and the reimbursement payment rate for the PromarkerD test in the United States. | 18/09/2023 |
The suspension of trading in the securities of Proteomics International Laboratories Ltd will be lifted immediately following the release by PIQ of an announcement regarding the licensing of the PromarkerD test in the US market. | 09/08/2022 |
Proteomics International and Sonic Healthcare USA sign binding and exclusive Letter of Intent regarding an exclusive licence for PromarkerD in the United States. Estimated 32 million people or eleven per cent of the American population live with diabetes - testing these patients with PromarkerD could help identify their risk of developing diabetic kidney disease. | 09/08/2022 |
The securities of Proteomics International Laboratories Ltd ("˜PIQ') will be suspended from quotation immediately under Listing Rule 17.2, at the request of PIQ, pending the release of an announcement. | 08/08/2022 |
The suspension of trading in the securities of Proteomics International Laboratories Ltd will be lifted from the commencement of trading on Monday, 5 July 2021, following the release by PIQ of an announcement regarding a presentation given at the American Diabetes Association's 81st Scientific Sessions, 25-29 June 2021. | 02/07/2021 |
Proteomics International Laboratories Ltd refers to its ASX release of 25 June 2021 titled "Modelling shows PromarkerD could save US payers $384 billion". Following consultation with ASX, and to ensure the findings from the study are not interpreted as forecast financial information under ASIC Regulatory Guide 170, Proteomics International has agreed to retract that Announcement. In retracting that Announcement, Proteomics International notes that investors should not rely on the information as a basis for making an investment decision about its shares. Importantly, shares in Proteomics International have not traded since release of the Announcement. The economic health benefit study was undertaken to support the Company's application for a unique reimbursement code for PromarkerD in the US, and was conducted by independent consultant, Boston Healthcare Associates. | 02/07/2021 |
The Company requests an extension to the voluntary suspension of its securities pending the release of an announcement regarding the presentation given at the American Diabetes Association's 81st Scientific Sessions, 25-29 June 2021. The Company estimates that it will be able to lodge an announcement on or before the commencement of trading on Tuesday, 6 July 2021. | 02/07/2021 |
The securities of Proteomics International Laboratories Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of PIQ, pending the release of the presentation given at the American Diabetes Association's 81st Scientific Sessions, 25-29 June 2021. | 29/06/2021 |
listed entity carried for record purposes only | 16/04/2015 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 25/06/2020 | Paul House | 120,000 | $0.410 | $49,200 |
| 25/06/2020 | Roger Moore | 90,000 | $0.409 | $36,819 |
| 24/06/2020 | Richard Lipscombe | 37,500 | $0.410 | $15,375 |
| 12/09/2017 | Roger Moore | 65,000 | $0.200 | $13,000 |
| 30/12/2016 | Roger Moore | 12,000 | $0.250 | $3,000 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| James Williams | Chairman, Independent Director | 16/09/2024 |
| Richard Lipscombe | Managing Director | 16/04/2014 |
| Jacqueline Gray | CFO | 10/06/2021 |
| Aaron Brinkworth | Independent Director | 08/11/2024 |
| Paul House | Non Exec Director | 22/11/2017 |
| Neville Gardiner | Non Exec Director | 16/11/2021 |
| Karen Logan | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Roger Moore | Non Exec Director | 14/10/2016 | 08/11/2024 |
| Robyn Elliott | Independent Director | 16/11/2021 | 12/08/2024 |
| Terry Sweet | Non Exec Chairman | 16/04/2014 | 25/11/2021 |
| John Dunlop | Non Exec Director | 16/04/2014 | 22/11/2018 |
| Bill Parker | Non Exec Director | 16/04/2014 | 28/06/2016 |
| James Moses | Executive Director | 16/10/2015 | 28/06/2016 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
